Drug
rhDNase I
rhDNase I is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 50.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
1(33%)
Results Posted
100%(1 trials)
Terminated
1(33%)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(1)
Terminated(1)
Detailed Status
Recruiting1
Completed1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
50.0%
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
recruiting133%
completed133%
terminated133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingphase_1
Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion.
NCT07361224
completedphase_1
DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1)
NCT04409925
terminatedphase_1
rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease
NCT02702518
Clinical Trials (3)
Showing 3 of 3 trials
NCT07361224Phase 1
Investigator Initiated Study to Assess the Safety of Combination of CLS-015 With Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive Large B Cell Lymphoma at Lymphodepletion.
NCT04409925Phase 1
DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1)
NCT02702518Phase 1
rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3